Squarepoint Ops LLC Takes $664,000 Position in Artivion, Inc. $AORT

Squarepoint Ops LLC bought a new position in Artivion, Inc. (NYSE:AORT) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 21,362 shares of the company’s stock, valued at approximately $664,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its position in shares of Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Artivion by 447.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company’s stock worth $168,000 after acquiring an additional 4,422 shares during the last quarter. James Investment Research Inc. bought a new position in shares of Artivion in the second quarter worth approximately $210,000. Atria Investments Inc bought a new stake in Artivion in the 2nd quarter worth $244,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Artivion during the second quarter valued at about $248,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AORT has been the topic of a number of recent analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $51.00 price objective on shares of Artivion in a research report on Wednesday, December 17th. JMP Securities upped their price target on Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. Oppenheimer reiterated an “outperform” rating and set a $50.00 target price on shares of Artivion in a report on Friday, November 7th. Stifel Nicolaus lifted their target price on shares of Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Finally, Citizens Jmp boosted their price target on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $49.11.

Artivion Price Performance

Shares of Artivion stock opened at $47.20 on Wednesday. The stock’s fifty day moving average is $45.18 and its 200 day moving average is $39.65. The stock has a market cap of $2.24 billion, a P/E ratio of -196.67 and a beta of 1.60. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93.

Artivion (NYSE:AORT) last released its earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The company had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. The business’s revenue was up 18.9% on a year-over-year basis. Sell-side analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Buying and Selling at Artivion

In other Artivion news, SVP Marshall S. Stanton sold 47,376 shares of Artivion stock in a transaction on Friday, November 21st. The shares were sold at an average price of $45.04, for a total value of $2,133,815.04. Following the completion of the transaction, the senior vice president directly owned 44,753 shares of the company’s stock, valued at $2,015,675.12. This trade represents a 51.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO James P. Mackin sold 34,210 shares of the business’s stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $45.86, for a total value of $1,568,870.60. Following the transaction, the chief executive officer directly owned 800,993 shares in the company, valued at approximately $36,733,538.98. This represents a 4.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 234,511 shares of company stock worth $10,612,452 over the last three months. 8.10% of the stock is owned by company insiders.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.